• Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests.
  • Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care.
  • We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company.
  • Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.

At Axis-Shield, innovation is fundamental to our business.

 

There is an increasing need for new diagnostic tests in many disease areas, including those associated with an increasingly ageing population. Identifying these diseases quickly and efficiently can be vital in maintaining a patient's quality of life. New drug modalities are evolving alongside innovative diagnostics, which is leading to improved patient management and monitoring of treatment efficacy.

The core focus of our business continues to be on innovation and the development of new markers that will increase testing and improve patient care.

 

We are continually striving to develop improved methods to diagnose disease, employing both in-house expertise and our links with external centres of excellence. More than 50 scientists are employed in this capacity in our research centres in Norway and Scotland.

 

Since our inception, we have successfully implemented our strategy of growth through the development and marketing of novel diagnostic tests in areas of clinical need. Key products illustrating this include:

  • Homocysteine for identifying increased risk of cardiovascular and neurodegenerative diseases
  • Anti-CCP for early detection of rheumatoid arthritis
  • Active-B12 for improved detection of vitamin B12 deficiency
  • HbA1c for monitoring disease control in diabetes

In line with this continuing strategy, we are working on markers in a number of different clinical areas including our exciting test for Heparin Binding Protein - a new marker for diagnosis and monitoring of severe sepsis.

 

We welcome discussion with organisations or individuals wishing to accelerate development, clinical evaluation and commercialisation of any novel markers and potential clinical utility.

 

Please contact us for more information.

Axis-Shield at a Glance

A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.

› More about our tests

Focus on Homocysteine

As a general marker of overall health status, few tests carry greater predictive weight than Homocysteine. The amount of Homocysteine in your blood is one of the best independent indicators of how healthy you are.

 

› Axis-Shield Homocysteine assays

© Axis-Shield plc 2011. All rights reserved. Registered in Scotland No. SC145200 - Sitemap | Terms-of-Use | Accessibility | Disclaimer
Luna Place, The Technology Park, Dundee, DD2 1XA, Scotland.
Diagnostics for the laboratory & the point of care in areas of clinical need including diabetes, cardiovascular & neurodegenerative disease, rheumatoid arthritis & infectious disease.